DACS 272 Neurologic deficits in the years following ART initiation among subjects in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized.

Slides:

Advertisements

Similar presentations

Slide 1 of 22 IAS–USA Victor G. Valcour, MD Professor of Geriatric Medicine University of California San Francisco Emerging Issues in HIV, Aging, and Cognition.

Advertisements

High rates of survival, virologic suppression and immune reconstitution among patients receiving second-line ART in the Indian national programme B.B.

Cognitive, neurological and adaptive behaviour functioning among children with perinatally-acquired HIV infection Anita Shet, Smitha Holla, Vijaya Raman,

Antiretroviral therapy eligibility at enrollment and time to treatment initiation in Ethiopia Chloe A. Teasdale 1, Chunhui Wang 1, Sileshi Lulseged 1,

Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,

Characteristics of clients undergoing repeat HIV counseling and testing compared to clients newly-tested for HIV in Nyanza Province Oyaro P, Owuor K, Ng’eno.

High Risk Sharing Behaviors: The Effect of Sex within Injecting Partnerships Meghan D. Morris, PhD, MPH Postdoctoral Research Fellow Department of Epidemiology.

* Pre- and Post-HAART eras defined as before or after 07/01/96. ** For comparison of HIV positive to HIV negative IRs within Pre- or Post-HAART eras. ***

This work was supported by National Institute of Health (NIH) grants including the Neurologic AIDS Research Consortium grant NS32228 from NINDS, the AIDS.

HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,

HIV NEUROBEHAVIORAL RESEARCH PROGRAM | UNIVERSITY OF CALIFORNIA, SAN DIEGO CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH | UNIVERSITY OF CALIFORNIA,

Highlights of MACS and WIHS Protocol and Cohorts Lisa Jacobson Stephen Gange May 25, 2005 Not for distribution or publication outside the Multicenter AIDS.

Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.

Introduction DCDOH supports HIV test and treat activities - increased number of HIV tests performed, emphasis on earlier linkage to care. Limited data.

Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.

Metabolic Syndrome, Diabetes, and Cognitive Impairment in the Era of Combination Antiretroviral Therapy Allen McCutchan 1, Jennifer Marquie-Beck 1, Scott.

The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.

Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents Roger Bedimo, MD; Song Zhang, PhD; Henning.

Fatal and Non-fatal Hepatic Failure in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California (KP), a Large Managed Care Organization.

Increased clinical events in HIV-infected patients who achieve full virologic suppression but fail to attain a CD4 count ≥ 200 cells/mm 3 after one year.

Slide 1 of 25 From VG Valcour, MD, at Washington, DC: June 18, 2013, IAS-USA. IAS–USA Victor G. Valcour, MD Professor of Geriatric Medicine University.

Obtaining housing associated with achieving abstinence after detoxification in adults with addiction Tae Woo Park, Christine Maynié-François, Richard Saitz.

Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.

Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.

Occult hepatitis B virus (HBV) and hepatitis C virus (HCV) viremia in women with and at-risk for HIV/AIDS Taylor L, Gholam P, Delong A, Rompalo A, Klein.

Determinants of long term adherence to antiretroviral drugs among adults followed over 54 months in Dakar (Senegal) M. Ciss 1, A. Desclaux 2, K. Diop 3,

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.

Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,

Changes in Renal Function in Patients Treated with Tenofovir DF (TDF) Compared to Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Joel E. Gallant,

Background ●Osteoporosis is characterized by low bone mass leading to increased bone fragility and increase in fracture risk, particularly the vertebrae,

Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.

Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,

Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.

Factors Associated with Persistent Neurocognitive Impairment Despite Long-term HAART in Patients with HIV-Dementia V Tozzi, P Balestra, MF Salvatori, C.

Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.

Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.

HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.

1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.

Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.

Failure to Initiate ART, Loss to Follow-up and Mortality among HIV-infected Patients during the pre-ART period in Uganda Elvin H. Geng 1, Winnie Muyindike.

Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.

Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,

ION-4  Design LDV/SOF Open-label ION-4 Study: LDV/SOF in HIV co-infection W12 ≥ 18 years Chronic HCV infection Genotype 1 or 4 HCV RNA ≥ 10,000 IU/ml.

Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.

HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients Roger Bedimo, MD; Henning Drechsler, MD; Song Zhang, PhD;

THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.

Sub module 3 Pre-ART and ART registers. Purpose of registers Key individual information for: Facilitating patient management by the identification of.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Long-Term Comparison of Nevirapine Versus Efavirenz When Combined with Other Antiretroviral Drugs in HIV-1 Positive Antiretroviral-Naïve Persons- The NNRTI.

Cumulative plasma HIV-1 level as a novel tool to evaluate antiretroviral therapy efficacy at the individual and public health levels Presented by Viviane.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influence of the Timing of Antiretroviral Therapy.

Neurologic Effects Associated With Efavirenz Generally Mild, Transient Slideset on: Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological.

Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

Higher HDL, better brain

undetectable (undetectable-6.25)

Conclusions & Implications

ART and toxicities: CNS

Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda

Factors Associated with Low Bone Mineral Density (BMD) in a Large Cohort of HIV-Infected U.S. Adults – Baseline Results from the SUN Study # 836 ET Overton1,

Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.

2018 Postgraduate Research Symposium: Exploring opportunities

Comparison of NNRTI vs PI/r

for the VACS Project Team

Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD

Switch to ATV/r monotherapy

Presentation transcript:

DACS 272 Neurologic deficits in the years following ART initiation among subjects in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) cohort M. Smurzynski 1, M. Yang 1, K. Robertson 2, A.C. Collier 3, K. Wu 1, R.J. Bosch 1, R.J. Ellis 4 1 Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston 2 University of North Carolina, Neurology, Chapel Hill, 3 University of Washington, Harborview Medical Center, Medicine/Infectious Diseases, Seattle 4 University of California, San Diego, Neurosciences, HIV Neurobehavioral Research Center THAB0106

Background/Objective Previous studies focused on concurrent risk factors for neurocognitive impairment – Lower CD4 nadir, older, comorbidities, vascular risk – ART regimens: PI vs NNRTI; CPE Objective: To identify risk factors for poor neurocognitive outcomes during follow-up on ART

Design, Participants Design: Prospective observational cohort Participants: 1,599 HIV+ individuals enrolled in ALLRT and having undergone neuropsychological testing – Antiretroviral naïve prior to parent study entry

Timeline for ascertainment of study predictors and outcomes ACTG Parent Study ALLRT Enrollment 1 st NP Testing 2 nd NP Testing (48 weeks) Repeat NP Testing - every 48 Weeks Ascertain risk indicators /predictors: stroke, hepatitis C Serostatus, etc. Ascertain longitudinal neurocognitive outcomes: NPZ-3 and NPZ wks treatment2-9 years follow-up

ALLRT NeuroScreen Tests Trailmaking Test - Part A Trailmaking Test - Part B Digit-Symbol Test (Added later: HVLT)

Primary Outcome: serial NPZ-3 scores Overall performance: mean z-scores across the 3 tests (NPZ-3) Impairment: ≤ -2.0 SD on one test or ≤ -1.0 on two tests Uni- and multi-variable repeated measures regression models evaluated predictors of NPZ-3 worsening. Variables with p< 0.10 eligible to enter multivariable models

Predictors evaluated Behavioral risks – smoking, injection drug use (IDU) HIV disease and treatment indicators – Years since parent entry (surrogate for ART duration) – pre-ART CD4 – ART regimen type – time-updated plasma viral load (PVL) and CD4 Coinfections – hepatitis B surface antigen (HBsAg) – hepatitis C virus (HCV) serostatus Other brain comorbidities – history of stroke

Representative example of serial NPZ-3 scores for one participant according to continuous vs binary outcome Continuous Discrete

Characteristics at Parent Study Entry Median (IQR) or N (%) Age at parent study entry39 (32, 45) Gender male1,312 (82%) White Non-Hispanic928 (58%) Black Non-Hispanic671 (42%) Injection drug use ever124 (8%) Hepatitis B (HBsAg) +44 (3%) Hepatitis C status Positive116 (7%) Nadir CD4 (cells/ul)189 (61, 298)

HIV disease and treatment indicators Protective: NC decline less likely Susceptibility: NC decline more likely

Comorbidity risks / predictors Protective: NC decline less likely Susceptibility: NC decline more likely

Summary: Multivariable Predictors of Decline Hazard of NP decline reduced with: Longer duration of ART (time since parent entry) Better immune recovery:  time-updated CD4 (>350 vs <50) Hazard of NP decline increased with: History of stroke prior to parent entry Hazard of NP decline not affected by: Age (in this study ) CD4 nadir (>200 or vs <=50) Virologic suppression on ART (< 200 copies; 95% in years 1-3) ARV drug class (PI/NRTI vs NRTI only, etc) Smoking history at parent entry IDU history Hepatitis B and C seropositivity

Summary: During Longitudinal Follow-up… Longer duration of ART protective with respect to neurocognitive function Continuing CD4 recovery linked to protection – Prior studies: Starting ART before prolonged immunosuppression enhances CD4 recovery – Cross-sectionally, CD4 nadir linked to prevalent impairment Specific comorbidities confer increased risk of poor outcomes – Stroke: marker of vascular risk? – Vascular risk factors highly prevalent in aging HIV+ (metabolic syndrome)

Acknowledgements Co-authors ACTG Sites NIH (NIMH) HIV+ study participants

Backup Slides

Study Comparison ALLRTCHARTER N1, Epoch Years f/u – Median (IQR)6 (2, 9) 3 (1.5-4) Age, years – Median (IQR)39 (32, 45)44 (35, 51) Past ART Exposurenaïve before parent enrollTypically extensive Current cART100%70% CD4 nadir – Median (IQR)189 (IQR 61, 298)184 (49, 230) CD4 entry – Median (IQR)218 (continuing increases)459 (289, 644) Virologic suppression95% at year 258% of those on cART Outcome Measure Repeated NPZ-3 [unimpaired to impaired] Clinically significant decline by sRCS NP tests3 tests, 2 domains15 tests, 7 domains

Training Videos